Dr. Rugo on the Future of Extended Adjuvant Hormone Therapy for Breast Cancer

Hope S. Rugo, MD
Published Online: Monday, Aug 28, 2017



Hope S. Rugo, MD, a professor of medicine and director of the Breast Oncology Clinical Trials Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco discusses the future of extended adjuvant hormone therapy for patients with breast cancer.

Longer-term follow-up is important to determine the benefit of adjuvant hormone therapy, explains Rugo. There is a study with a 7-year follow-up for patients receiving hormone therapy, but it is still unknown whether one can expect to see any different results after long-term treatment.

Additionally, genomic predictors will be beneficial to determine which patients should be treated with this therapy and this is currently being investigated, states Rugo.
 


Hope S. Rugo, MD, a professor of medicine and director of the Breast Oncology Clinical Trials Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco discusses the future of extended adjuvant hormone therapy for patients with breast cancer.

Longer-term follow-up is important to determine the benefit of adjuvant hormone therapy, explains Rugo. There is a study with a 7-year follow-up for patients receiving hormone therapy, but it is still unknown whether one can expect to see any different results after long-term treatment.

Additionally, genomic predictors will be beneficial to determine which patients should be treated with this therapy and this is currently being investigated, states Rugo.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections: 15th Annual International Congress on the Future of Breast Cancer®Oct 06, 20172.0
Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast CancerJan 30, 20181.5
Publication Bottom Border
Border Publication